Hydroxychloroquine and chloroquine retinal safety concerns during COVID-19 outbreak.
Identifieur interne : 000B98 ( Main/Corpus ); précédent : 000B97; suivant : 000B99Hydroxychloroquine and chloroquine retinal safety concerns during COVID-19 outbreak.
Auteurs : Massimo Nicol ; Lorenzo Ferro Desideri ; Matteo Bassetti ; Carlo Enrico TraversoSource :
- International ophthalmology [ 1573-2630 ] ; 2021.
English descriptors
- KwdEn :
- MESH :
- chemical , pharmacology : Antimalarials, Chloroquine, Hydroxychloroquine.
- drug effects : Retina.
- drug therapy : COVID-19.
- epidemiology : COVID-19.
- Disease Outbreaks, Humans, Pandemics, SARS-CoV-2.
Abstract
PURPOSE
The current coronavirus disease 2019 (COVID-19) has been declared by the World Health Organization a global pandemic. Chloroquine (CQ) and hydroxychloroquine (HCQ) have been largely adopted in the clinical setting for the management of SARS-CoV-2 infection; however, their known retinal toxicity has raised some safety concerns, especially considering the higher-dosage employed for COVID-19 patients as compared with their suggested posology for their usual indications, including systemic lupus erythematosus and other rheumatic diseases. In this review, we will discuss the optimal dosages recommended for COVID-19 patients when treated with HCQ and CQ.
METHODS
A comprehensive literature search was performed in PubMed, Cochrane library, Embase and Scopus, by using the following search terms: "chloroquine retinal toxicity" and "hydroxychloroquine retinal toxicity" alone or in combination with "coronavirus", "COVID-19", " SARS-CoV-2 infection " from inception to August 2020.
RESULTS
Although there is still no consistent evidence about HCQ/CQ retinal toxicity in patients with COVID-19, these possible drug-related retinal adverse events may represent a major safety concern. For this reason, appropriate screening strategies, including telemedicine, should be developed in the near future.
CONCLUSION
A possible future clinical perspective for patients with COVID-19 treated with HCQ/CQ could reside in the multidisciplinary collaboration between ophthalmologists monitoring the risk of HCQ/CQ-related retinal toxicity and those physicians treating COVID-19 infection.
DOI: 10.1007/s10792-020-01593-0
PubMed: 32946004
PubMed Central: PMC7499926
Links to Exploration step
pubmed:32946004Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Hydroxychloroquine and chloroquine retinal safety concerns during COVID-19 outbreak.</title><author><name sortKey="Nicol, Massimo" sort="Nicol, Massimo" uniqKey="Nicol M" first="Massimo" last="Nicol">Massimo Nicol</name><affiliation><nlm:affiliation>IRCCS Ospedale Policlinico San Martino, University Eye Clinic of Genoa, Genova, Italy. massimonicolo@gmail.com.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, Genova, Italy. massimonicolo@gmail.com.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Macula Onlus Foundation, Genova, Italy. massimonicolo@gmail.com.</nlm:affiliation></affiliation></author><author><name sortKey="Ferro Desideri, Lorenzo" sort="Ferro Desideri, Lorenzo" uniqKey="Ferro Desideri L" first="Lorenzo" last="Ferro Desideri">Lorenzo Ferro Desideri</name><affiliation><nlm:affiliation>IRCCS Ospedale Policlinico San Martino, University Eye Clinic of Genoa, Genova, Italy.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, Genova, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Bassetti, Matteo" sort="Bassetti, Matteo" uniqKey="Bassetti M" first="Matteo" last="Bassetti">Matteo Bassetti</name><affiliation><nlm:affiliation>Infectious Diseases Clinic, Department of Health Sciences, University of Genova and Ospedale Policlinico San Martino- IRCCS Per L'Oncologia, Genova, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Traverso, Carlo Enrico" sort="Traverso, Carlo Enrico" uniqKey="Traverso C" first="Carlo Enrico" last="Traverso">Carlo Enrico Traverso</name><affiliation><nlm:affiliation>IRCCS Ospedale Policlinico San Martino, University Eye Clinic of Genoa, Genova, Italy.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, Genova, Italy.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2021">2021</date><idno type="RBID">pubmed:32946004</idno><idno type="pmid">32946004</idno><idno type="doi">10.1007/s10792-020-01593-0</idno><idno type="pmc">PMC7499926</idno><idno type="wicri:Area/Main/Corpus">000B98</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000B98</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Hydroxychloroquine and chloroquine retinal safety concerns during COVID-19 outbreak.</title><author><name sortKey="Nicol, Massimo" sort="Nicol, Massimo" uniqKey="Nicol M" first="Massimo" last="Nicol">Massimo Nicol</name><affiliation><nlm:affiliation>IRCCS Ospedale Policlinico San Martino, University Eye Clinic of Genoa, Genova, Italy. massimonicolo@gmail.com.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, Genova, Italy. massimonicolo@gmail.com.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Macula Onlus Foundation, Genova, Italy. massimonicolo@gmail.com.</nlm:affiliation></affiliation></author><author><name sortKey="Ferro Desideri, Lorenzo" sort="Ferro Desideri, Lorenzo" uniqKey="Ferro Desideri L" first="Lorenzo" last="Ferro Desideri">Lorenzo Ferro Desideri</name><affiliation><nlm:affiliation>IRCCS Ospedale Policlinico San Martino, University Eye Clinic of Genoa, Genova, Italy.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, Genova, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Bassetti, Matteo" sort="Bassetti, Matteo" uniqKey="Bassetti M" first="Matteo" last="Bassetti">Matteo Bassetti</name><affiliation><nlm:affiliation>Infectious Diseases Clinic, Department of Health Sciences, University of Genova and Ospedale Policlinico San Martino- IRCCS Per L'Oncologia, Genova, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Traverso, Carlo Enrico" sort="Traverso, Carlo Enrico" uniqKey="Traverso C" first="Carlo Enrico" last="Traverso">Carlo Enrico Traverso</name><affiliation><nlm:affiliation>IRCCS Ospedale Policlinico San Martino, University Eye Clinic of Genoa, Genova, Italy.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, Genova, Italy.</nlm:affiliation></affiliation></author></analytic><series><title level="j">International ophthalmology</title><idno type="eISSN">1573-2630</idno><imprint><date when="2021" type="published">2021</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antimalarials (pharmacology)</term><term>COVID-19 (drug therapy)</term><term>COVID-19 (epidemiology)</term><term>Chloroquine (pharmacology)</term><term>Disease Outbreaks (MeSH)</term><term>Humans (MeSH)</term><term>Hydroxychloroquine (pharmacology)</term><term>Pandemics (MeSH)</term><term>Retina (drug effects)</term><term>SARS-CoV-2 (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antimalarials</term><term>Chloroquine</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Retina</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>COVID-19</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>COVID-19</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Disease Outbreaks</term><term>Humans</term><term>Pandemics</term><term>SARS-CoV-2</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>PURPOSE</b></p><p>The current coronavirus disease 2019 (COVID-19) has been declared by the World Health Organization a global pandemic. Chloroquine (CQ) and hydroxychloroquine (HCQ) have been largely adopted in the clinical setting for the management of SARS-CoV-2 infection; however, their known retinal toxicity has raised some safety concerns, especially considering the higher-dosage employed for COVID-19 patients as compared with their suggested posology for their usual indications, including systemic lupus erythematosus and other rheumatic diseases. In this review, we will discuss the optimal dosages recommended for COVID-19 patients when treated with HCQ and CQ.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>A comprehensive literature search was performed in PubMed, Cochrane library, Embase and Scopus, by using the following search terms: "chloroquine retinal toxicity" and "hydroxychloroquine retinal toxicity" alone or in combination with "coronavirus", "COVID-19", " SARS-CoV-2 infection " from inception to August 2020.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>Although there is still no consistent evidence about HCQ/CQ retinal toxicity in patients with COVID-19, these possible drug-related retinal adverse events may represent a major safety concern. For this reason, appropriate screening strategies, including telemedicine, should be developed in the near future.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSION</b></p><p>A possible future clinical perspective for patients with COVID-19 treated with HCQ/CQ could reside in the multidisciplinary collaboration between ophthalmologists monitoring the risk of HCQ/CQ-related retinal toxicity and those physicians treating COVID-19 infection.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32946004</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>04</Day></DateCompleted><DateRevised><Year>2021</Year><Month>03</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2630</ISSN><JournalIssue CitedMedium="Internet"><Volume>41</Volume><Issue>2</Issue><PubDate><Year>2021</Year><Month>Feb</Month></PubDate></JournalIssue><Title>International ophthalmology</Title><ISOAbbreviation>Int Ophthalmol</ISOAbbreviation></Journal><ArticleTitle>Hydroxychloroquine and chloroquine retinal safety concerns during COVID-19 outbreak.</ArticleTitle><Pagination><MedlinePgn>719-725</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10792-020-01593-0</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">The current coronavirus disease 2019 (COVID-19) has been declared by the World Health Organization a global pandemic. Chloroquine (CQ) and hydroxychloroquine (HCQ) have been largely adopted in the clinical setting for the management of SARS-CoV-2 infection; however, their known retinal toxicity has raised some safety concerns, especially considering the higher-dosage employed for COVID-19 patients as compared with their suggested posology for their usual indications, including systemic lupus erythematosus and other rheumatic diseases. In this review, we will discuss the optimal dosages recommended for COVID-19 patients when treated with HCQ and CQ.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A comprehensive literature search was performed in PubMed, Cochrane library, Embase and Scopus, by using the following search terms: "chloroquine retinal toxicity" and "hydroxychloroquine retinal toxicity" alone or in combination with "coronavirus", "COVID-19", " SARS-CoV-2 infection " from inception to August 2020.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Although there is still no consistent evidence about HCQ/CQ retinal toxicity in patients with COVID-19, these possible drug-related retinal adverse events may represent a major safety concern. For this reason, appropriate screening strategies, including telemedicine, should be developed in the near future.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">A possible future clinical perspective for patients with COVID-19 treated with HCQ/CQ could reside in the multidisciplinary collaboration between ophthalmologists monitoring the risk of HCQ/CQ-related retinal toxicity and those physicians treating COVID-19 infection.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nicolò</LastName><ForeName>Massimo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>IRCCS Ospedale Policlinico San Martino, University Eye Clinic of Genoa, Genova, Italy. massimonicolo@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, Genova, Italy. massimonicolo@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Macula Onlus Foundation, Genova, Italy. massimonicolo@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferro Desideri</LastName><ForeName>Lorenzo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>IRCCS Ospedale Policlinico San Martino, University Eye Clinic of Genoa, Genova, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, Genova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bassetti</LastName><ForeName>Matteo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Infectious Diseases Clinic, Department of Health Sciences, University of Genova and Ospedale Policlinico San Martino- IRCCS Per L'Oncologia, Genova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Traverso</LastName><ForeName>Carlo Enrico</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>IRCCS Ospedale Policlinico San Martino, University Eye Clinic of Genoa, Genova, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, Genova, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>09</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Int Ophthalmol</MedlineTA><NlmUniqueID>7904294</NlmUniqueID><ISSNLinking>0165-5701</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000962">Antimalarials</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>886U3H6UFF</RegistryNumber><NameOfSubstance UI="D002738">Chloroquine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000962" MajorTopicYN="N">Antimalarials</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002738" MajorTopicYN="N">Chloroquine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004196" MajorTopicYN="N">Disease Outbreaks</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="Y">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012160" MajorTopicYN="N">Retina</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Chloroquine</Keyword><Keyword MajorTopicYN="N">Coronavirus</Keyword><Keyword MajorTopicYN="N">Hydroxychloroquine</Keyword><Keyword MajorTopicYN="N">Retina</Keyword><Keyword MajorTopicYN="N">Retinal safety</Keyword><Keyword MajorTopicYN="N">SARCoV-2</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>05</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>09</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>9</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>18</Day><Hour>12</Hour><Minute>14</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32946004</ArticleId><ArticleId IdType="doi">10.1007/s10792-020-01593-0</ArticleId><ArticleId IdType="pii">10.1007/s10792-020-01593-0</ArticleId><ArticleId IdType="pmc">PMC7499926</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cucinotta D, Vanelli M (2020) WHO declares COVID-19 a pandemic. Acta Biomed 91(1):157–160</Citation><ArticleIdList><ArticleId IdType="pubmed">32191675</ArticleId><ArticleId IdType="pmcid">7569573</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou D, Dai SM, Tong Q (2020) COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrob Chemother 75:1667–1670. https://doi.org/10.1093/jac/dkaa114</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkaa114</ArticleId><ArticleId IdType="pubmed">32196083</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalia S, Dutz JP (2007) New concepts in antimalarial use and mode of action in dermatology. DermatolTher 20(4):160–174</Citation></Reference><Reference><Citation>Plantone D, Koudriavtseva T (2018) Current and future use of chloroquine and hydroxychloroquine in infectious, immune, neoplastic, and neurological diseases: a mini-review. Clin Drug Investig 38(8):653–671</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40261-018-0656-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M et al (2020) Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30(3):269–271</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-020-0282-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P et al (2020) In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 71:732–739. https://doi.org/10.1093/cid/ciaa237</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa237</ArticleId><ArticleId IdType="pubmed">32150618</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinha N, Balayla G (2020) Hydroxychloroquine and covid-19. Postgrad Med J 96(1139):550–555. https://doi.org/10.1136/postgradmedj-2020-137785</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/postgradmedj-2020-137785</ArticleId><ArticleId IdType="pubmed">32295814</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao J, Tian Z, Yang X (2020) Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 14(1):72–73</Citation><ArticleIdList><ArticleId IdType="doi">10.5582/bst.2020.01047</ArticleId></ArticleIdList></Reference><Reference><Citation>Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M et al (2020) Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 56:105949</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2020.105949</ArticleId></ArticleIdList></Reference><Reference><Citation>Italian Society of Infectious and Tropical disease Guidelines 2020. https://www.simit.org/medias/1555-covid19-linee-guida-trattamento-01mar.pdf</Citation></Reference><Reference><Citation>Dutch Center of Disease control guidelines 2020. https://lci.rivm.nl/covid-19/bijlage/behandeladvies</Citation></Reference><Reference><Citation>Raines MF, Bhargava SK, Rosen ES (1989) The blood-retinal barrier in chloroquine retinopathy. Invest Ophthalmol Vis Sci 30(8):1726–1731</Citation><ArticleIdList><ArticleId IdType="pubmed">2759787</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenthal AR, Kolb H, Bergsma D, Huxsoll D, Hopkins JL (1978) Chloroquine retinopathy in the rhesus monkey. Invest Ophthalmol Vis Sci 17(12):1158–1175</Citation><ArticleIdList><ArticleId IdType="pubmed">102610</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu C, Zhu L, Chan T, Lu X, Shen W, Madigan MC et al (2016) Chloroquine and hydroxychloroquine are novel inhibitors of human organic anion transporting polypeptide 1A2. J Pharm Sci 105(2):884–890</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jps.24663</ArticleId></ArticleIdList></Reference><Reference><Citation>Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF (2016) Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). Ophthalmology 123(6):1386–1394</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2016.01.058</ArticleId></ArticleIdList></Reference><Reference><Citation>Melles RB, Marmor MF (2015) Pericentral retinopathy and racial differences in hydroxychloroquine toxicity. Ophthalmology 122(1):110–116</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2014.07.018</ArticleId></ArticleIdList></Reference><Reference><Citation>Melles RB, Marmor MF (2014) The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol 132(12):1453–1460</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaophthalmol.2014.3459</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe F, Marmor MF (2010) Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res (Hoboken) 62(6):775–784</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.20133</ArticleId></ArticleIdList></Reference><Reference><Citation>Yusuf IH, Foot B, Galloway J, Ardern-Jones MR, Watson SL, Yelf C et al (2018) The Royal College of Ophthalmologists recommendations on screening for hydroxychloroquine and chloroquine users in the United Kingdom: executive summary. Eye (Lond) 32(7):1168–1173</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41433-018-0136-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruamviboonsuk P, Lai TYY, Chang A, Lai CC, Mieler WF, Lam DSC et al (2020) Chloroquine and hydroxychloroquine retinal toxicity consideration in the treatment of COVID-19. Asia Pac J Ophthalmol (Phila) 9(2):85–87</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/APO.0000000000000289</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung LS, Neal JW, Wakelee HA, Sequist LV, Marmor MF (2015) Rapid onset of retinal toxicity from high-dose hydroxychloroquine given for cancer therapy. Am J Ophthalmol 160(4):799–805.e1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajo.2015.07.012</ArticleId></ArticleIdList></Reference><Reference><Citation>Navajas EV, Krema H, Hammoudi DS, Lipton JH, Simpson ER, Boyd S et al (2015) Retinal toxicity of high-dose hydroxychloroquine in patients with chronic graft-versus-host disease. Can J Ophthalmol 50(6):442–450</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcjo.2015.08.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Magulike NO, Ihenacho HN, Ike VO (1993) Chloroquine retinopathy in Nigerian patients with heart block. Eye (Lond) 7(Pt 4):591–593</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/eye.1993.128</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandya HK, Robinson M, Mandal N, Shah VA (2015) Hydroxychloroquine retinopathy: a review of imaging. Indian J Ophthalmol 63(7):570–574</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0301-4738.167120</ArticleId></ArticleIdList></Reference><Reference><Citation>Melles RB, Marmor MF (2016) The Prevalence of Hydroxychloroquine Retinopathy and Toxic Dosing, and the Role of the Ophthalmologist in Reducing Both. Am J Ophthalmol 170:240</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajo.2016.06.045</ArticleId></ArticleIdList></Reference><Reference><Citation>Marmor MF (2012) Comparison of screening procedures in hydroxychloroquine toxicity. Arch Ophthalmol 130(4):461–469</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archophthalmol.2011.371</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Padilla JA, Hedges TR 3rd, Monson B, Srinivasan V, Wojtkowski M, Reichel E et al (2007) High-speed ultra-high-resolution optical coherence tomography findings in hydroxychloroquine retinopathy. Arch Ophthalmol 125(6):775–780</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archopht.125.6.775</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen E, Brown DM, Benz MS, Fish RH, Wong TP, Kim RY et al (2010) Spectral domain optical coherence tomography as an effective screening test for hydroxychloroquine retinopathy (the "flying saucer" sign). ClinOphthalmol 4:1151–1158</Citation></Reference><Reference><Citation>Browning DJ, Lee C (2014) Relative sensitivity and specificity of 10–2 visual fields, multifocal electroretinography, and spectral domain optical coherence tomography in detecting hydroxychloroquine and chloroquine retinopathy. ClinOphthalmol 8:1389–1399</Citation></Reference><Reference><Citation>Penrose PJ, Tzekov RT, Sutter EE, Fu AD, Allen AW Jr, Fung WE et al (2003) Multifocal electroretinography evaluation for early detection of retinal dysfunction in patients taking hydroxychloroquine. Retina 23(4):503–512</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00006982-200308000-00010</ArticleId></ArticleIdList></Reference><Reference><Citation>Marmor MF (2013) Fundus autofluorescence is not the best early screen for hydroxychloroquine toxicity. JAMA Ophthalmol 131(11):1487–1488</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaophthalmol.2013.4835</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorge A, Ung C, Young LH, Melles RB, Choi HK (2018) Hydroxychloroquine retinopathy—implications of research advances for rheumatology care. Nat Rev Rheumatol 14(12):693–703</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-018-0111-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Eye E. Hydroxychloroquine and chloroquine use for Covid-19. 2020.</Citation></Reference><Reference><Citation>Barazzoni R, Bischoff SC, Breda J, Wickramasinghe K, Krznaric Z, Nitzan D et al (2020) ESPEN expert statements and practical guidance for nutritional management of individuals with SARS-CoV-2 infection. ClinNutr 39(6):1631–1638. https://doi.org/10.1016/j.clnu.2020.03.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clnu.2020.03.022</ArticleId></ArticleIdList></Reference><Reference><Citation>Titus EO (1989) Recent developments in the understanding of the pharmacokinetics and mechanism of action of chloroquine. Ther Drug Monit 11(4):369–379</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00007691-198907000-00001</ArticleId></ArticleIdList></Reference><Reference><Citation>Marmor MF (2017) Hydroxychloroquine Screening Alert: Change is in the Wind. Ophthalmic Surg Lasers Imaging Retina 48(2):96–98</Citation><ArticleIdList><ArticleId IdType="doi">10.3928/23258160-20170130-01</ArticleId></ArticleIdList></Reference><Reference><Citation>Institute of Tropical Medicine Antewerp, UniversiteitAntwerpen, CHU Saint-Pierre, et al. Interim Clinical Guidance for Patients Suspected of/Confirmed With Covid-19 in Belgium. 2020: 1–13. Available at: https://epidemio.wiv-isp.be/ID/Documents/Covid19/COVID-19_InterimGuidelines_Treatment_ENG.pdf . Accessed 23 Mar 2020.</Citation></Reference><Reference><Citation>Rathi S, Tsui E, Mehta N, Zahid S, Schuman JS (2017) The Current State of Teleophthalmology in the United States. Ophthalmology 124(12):1729–1734</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2017.05.026</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SK, Callaway NF, Wallenstein MB, Henderson MT, Leng T, Moshfeghi DM (2015) SUNDROP: six years of screening for retinopathy of prematurity with telemedicine. Can J Ophthalmol 50(2):101–106</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcjo.2014.11.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmer-Galler IE, Kimura AE, Gupta S (2015) Diabetic retinopathy screening and the use of telemedicine. CurrOpinOphthalmol 26(3):167–172</Citation></Reference><Reference><Citation>Kirkizlar E, Serban N, Sisson JA, Swann JL, Barnes CS, Williams MD (2013) Evaluation of telemedicine for screening of diabetic retinopathy in the Veterans Health Administration. Ophthalmology 120(12):2604–2610</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2013.06.029</ArticleId></ArticleIdList></Reference><Reference><Citation>Group AHSR, Chew EY, Clemons TE, Bressler SB, Elman MJ, Danis RP et al (2014) Randomized trial of a home monitoring system for early detection of choroidal neovascularization home monitoring of the Eye (HOME) study. Ophthalmology 121(2):535–44</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2013.10.027</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas S, Hodge W, Malvankar-Mehta M (2015) The Cost-Effectiveness Analysis of Teleglaucoma Screening Device. PLoS ONE 10(9):e0137913</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0137913</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B98 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000B98 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32946004
|texte= Hydroxychloroquine and chloroquine retinal safety concerns during COVID-19 outbreak.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32946004" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |